Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to Conditioning Regimen for Allogeneic HCT in High-Risk Acute Leukemia or MDS
NCT05139004Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yttrium Y 90-labeled basiliximab in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Maximum tolerated dose/recommended phase II dose and Incidence of toxicity. Started Jul 2022; status: active, not recruiting.
02
Drugs
yttrium Y 90-labeled basiliximab
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05139004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139004.